v3.26.1
Schedule of condensed interim consolidated statements of financial position (Details) - CAD ($)
Mar. 31, 2026
Dec. 31, 2025
Mar. 31, 2025
Dec. 31, 2024
Current assets        
Cash $ 1,933,539 $ 4,665,392 $ 1,225,990 $ 1,171,558
Trade and other receivables 4,211,999 3,798,016    
Scientific research and experimental development tax credits receivable 53,029 49,200    
Accrued revenues (Note 3) 2,605,273 2,724,647    
Inventories (Note 4) 6,031,752 6,389,739    
Prepaid expenses 80,479 59,348    
Security deposits and deposits on purchase of goods 1,384,895 1,313,447    
Loan receivable (Note 5) 77,347 77,347    
Current assets 16,378,312 19,077,136    
Non-current assets        
Property, plant and equipment (Note 6) 3,713,165 3,059,201    
Intangible assets (Note 7) 7,474,788 7,472,426    
Right-of-use assets (Note 8) 342,142 389,407    
Non-current assets 11,530,095 10,921,034    
Total assets 27,908,407 29,998,169    
Current liabilities        
Trade and other payables 9,644,069 10,456,567    
Customer advances (Note 9) 1,173,574 1,154,191    
Loans payable (Note10) 70,408 7,297,100    
Convertible debentures (Note 12A) 2,645,502 2,645,502    
Convertible debentures and derivative liability (Note 12B) 2,689,643 2,432,637    
Current portion of lease liabilities (Note 11) 41,983 92,580    
Current liabilities 16,265,179 24,078,577    
Non-current liabilities        
Lease liabilities (Note 11) 322,690 323,206    
Loans payable (Note 10) 8,130,123    
Total liabilities 24,717,991 24,401,783    
Shareholders' equity        
Share capital (Note 13) 86,654,171 86,606,375   54,994,088
Warrants (Note 14) 6,470,739 6,465,936    
Contributed surplus (Notes 15) 7,559,538 7,559,538    
Foreign exchange in translation of foreign operations (1,093,799) (801,802)    
Accumulated deficit (96,400,235) (94,233,661)    
Total shareholders' equity 3,190,415 5,596,387 $ (12,269,825) $ (11,417,055)
Total liabilities and shareholders' equity 27,908,407 $ 29,998,169    
Previously stated [member]        
Current assets        
Cash 1,933,539      
Trade and other receivables 4,211,999      
Scientific research and experimental development tax credits receivable 53,029      
Accrued revenues (Note 3) 2,605,273      
Inventories (Note 4) 6,031,752      
Prepaid expenses 80,479      
Security deposits and deposits on purchase of goods 1,384,895      
Loan receivable (Note 5) 77,347      
Current assets 16,378,312      
Non-current assets        
Property, plant and equipment (Note 6) 3,713,165      
Intangible assets (Note 7) 7,474,788      
Right-of-use assets (Note 8) 342,142      
Non-current assets 11,530,095      
Total assets 27,908,407      
Current liabilities        
Trade and other payables 9,594,638      
Customer advances (Note 9) 1,173,574      
Loans payable (Note10) 8,115,168      
Convertible debentures (Note 12A) 2,645,502      
Convertible debentures and derivative liability (Note 12B) 2,689,643      
Current portion of lease liabilities (Note 11) 41,983      
Current liabilities 24,260,508      
Non-current liabilities        
Lease liabilities (Note 11) 322,690      
Loans payable (Note 10)      
Total liabilities 24,583,197      
Shareholders' equity        
Share capital (Note 13) 86,654,171      
Warrants (Note 14) 6,470,739      
Contributed surplus (Notes 15) 7,559,538      
Foreign exchange in translation of foreign operations (1,092,439)      
Accumulated deficit (96,266,801)      
Total shareholders' equity 3,325,209      
Total liabilities and shareholders' equity 27,908,406      
Reclassification [Member]        
Current assets        
Cash      
Trade and other receivables      
Scientific research and experimental development tax credits receivable      
Accrued revenues (Note 3)      
Inventories (Note 4)      
Prepaid expenses      
Security deposits and deposits on purchase of goods      
Loan receivable (Note 5)      
Current assets      
Non-current assets        
Property, plant and equipment (Note 6)      
Intangible assets (Note 7)      
Right-of-use assets (Note 8)      
Non-current assets      
Total assets      
Current liabilities        
Trade and other payables      
Customer advances (Note 9)      
Loans payable (Note10) (8,044,760)      
Convertible debentures (Note 12A)      
Convertible debentures and derivative liability (Note 12B)      
Current portion of lease liabilities (Note 11)      
Current liabilities (8,044,760)      
Non-current liabilities        
Lease liabilities (Note 11)      
Loans payable (Note 10) 8,044,760      
Total liabilities      
Shareholders' equity        
Share capital (Note 13)      
Warrants (Note 14)      
Contributed surplus (Notes 15)      
Foreign exchange in translation of foreign operations      
Accumulated deficit      
Total shareholders' equity      
Total liabilities and shareholders' equity      
Adjustments [Member]        
Current assets        
Cash      
Trade and other receivables      
Scientific research and experimental development tax credits receivable      
Accrued revenues (Note 3)      
Inventories (Note 4)      
Prepaid expenses      
Security deposits and deposits on purchase of goods      
Loan receivable (Note 5)      
Current assets      
Non-current assets        
Property, plant and equipment (Note 6)      
Intangible assets (Note 7)      
Right-of-use assets (Note 8)      
Non-current assets      
Total assets      
Current liabilities        
Trade and other payables 49,431      
Customer advances (Note 9)      
Loans payable (Note10)      
Convertible debentures (Note 12A)      
Convertible debentures and derivative liability (Note 12B)      
Current portion of lease liabilities (Note 11)      
Current liabilities 49,431      
Non-current liabilities        
Lease liabilities (Note 11)      
Loans payable (Note 10) 85,363      
Total liabilities 134,794      
Shareholders' equity        
Share capital (Note 13)      
Warrants (Note 14)      
Contributed surplus (Notes 15)      
Foreign exchange in translation of foreign operations (1,360)      
Accumulated deficit (133,434)      
Total shareholders' equity (134,794)      
Total liabilities and shareholders' equity